1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Suzuken Co., Ltd.

Suzuken Co., Ltd.

15.90
EUR
+0.50
(+3.25%)
2.16BMarket Cap
Nov 12Next Earn
Suzuken Co., Ltd.
FRA:ZU1
(Frankfurt Stock Exchange)

Recent

price

15.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
17,666.15
18,756.16
19,106.91
20,050.39
19,864.49
22,476.23
21,653.82
22,370.31
22,783.65
24,342.72
23,863.47
25,385.89
26,904.32
14,717.36
15,813
17,782.63
- -
Revenue per Share
97.08
81.18
144.72
216.29
190.81
292.12
216.92
198.21
322.72
310.26
88.51
163.18
236.46
178.94
227.29
272.72
- -
Basic EPS, GAAP
85.75
514.55
423.26
-530.01
310.04
40.76
144.12
949.15
351.87
-412.56
86.75
-54.1
226.97
441.41
-551.66
112.4
- -
Free Cash Flow per Basic Share
56.36
50.92
45.44
45.45
50.92
51.55
69.61
54.41
64.74
74.28
75.98
72.3
73.58
38.77
46.04
50.74
- -
Dividend per Share
2,870.37
2,919.58
3,121.66
3,283.04
4,075.62
3,969.06
4,097.84
4,284.79
4,390.97
4,618.31
4,675.2
4,749.58
4,970.37
2,680.98
2,825.77
3,074.28
- -
Book Value per Share
2,602.44
2,645.27
2,883.08
3,070.66
3,826.15
3,754.86
3,917.02
4,123.92
4,241.64
4,494.05
4,573.25
4,622.48
4,837.83
2,608.6
2,741.77
2,958.42
- -
Tangible Book Value per Share
99
99
99
99
99
99
98
95
94
91
89
88
86
162
152
140
139
Basic Weighted Avg Shares
1,751,961
1,859,934
1,894,611
1,988,137
1,969,683
2,228,204
2,127,076
2,124,016
2,132,345
2,213,532
2,128,478
2,239,112
2,314,828
2,386,493
2,399,952
2,486,647
- -
Sales/Revenue/Turnover
0.31
0.41
0.6
0.9
0.67
1.63
0.88
0.93
1.28
1.47
0.43
0.9
1.41
1.46
1.55
1.46
- -
Operating Margin (%)
9,656
10,975
12,239
11,932
11,718
11,930
11,720
11,042
10,772
10,719
10,179
9,560
8,639
8,563
12,053
12,341
- -
Depreciation Expense
9,627
8,050
14,350
21,447
18,920
28,960
21,308
18,820
30,204
28,213
7,895
14,393
20,345
29,016
34,496
38,136
- -
Net Income, GAAP
42.07
49.11
38.44
39.94
35.72
35.53
33.79
34.15
33.21
32.36
36.31
35.63
33.59
32.23
31.39
29.75
- -
Effective Tax Rate (%)
0.55
0.43
0.76
1.08
0.96
1.3
1
0.89
1.42
1.27
0.37
0.64
0.88
1.22
1.44
1.53
- -
Profit Margin (%)
65,010
73,501
87,858
101,172
110,746
136,618
141,928
158,110
175,402
188,084
189,668
185,057
166,895
163,875
164,985
163,120
- -
Working Capital
157
462
370
432
1,124
90
15
6
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
284,851
289,758
309,826
325,994
367,797
393,947
396,495
406,424
401,623
412,706
417,909
418,061
411,524
416,427
407,419
416,010
- -
Total Equity
1.07
1.31
2.25
3.28
2.37
5.91
3.05
3.17
4.39
5.29
1.38
3.06
5.14
5.61
6.06
6.06
- -
Return on Invested Capital (%)
3.39
2.79
4.77
6.72
5.42
7.57
5.38
4.67
7.44
6.92
1.88
3.43
4.92
7.02
8.38
9.27
- -
Return on Capital (%)
3.42
2.8
4.79
6.75
5.46
7.61
5.4
4.7
7.49
6.94
1.9
3.45
4.91
7.01
8.38
9.27
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
140
135
135
Market Capitalization
- -
397,015
329,129

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
906,570
876,172
- -
Cash, Cash Equivalents & STI
148,281
141,671
- -
Accounts Receivable, Net
578,047
554,190
- -
Inventories
153,709
152,551
- -
Total Current Liabilities
743,600
713,052
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.56%
-0.08%
2.11%
Free Cash Flow
-35.12%
-148.02%
-118.77%
Net Income, GAAP
13.95%
39.14%
10.55%
Sales/Revenue/Turnover
1.15%
3.17%
3.61%
Total Cash Common Dividend
4.38%
1.07%
1.53%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2,399,952
2026
- -
- -
- -
- -
2,486,647
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
227.29
2026
- -
- -
- -
- -
272.72
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
46.04
2026
- -
- -
- -
- -
50.74
2027
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Suzuken Co., Ltd. (9987.T) operates as one of Japan's leading pharmaceutical wholesalers, engaging in the wholesale distribution of pharmaceuticals, medical devices, and healthcare products; manufacturing and sale of generic drugs and over-the-counter medicines; provision of logistics and supply chain management services for the healthcare sector; and operation of retail pharmacies and healthcare consulting services. The company offers a wide range of products including branded and generic prescription drugs, medical equipment, diagnostics, cosmetics, and animal health products under its own brands such as Suzuken generics and private-label items. Suzuken serves hospitals, clinics, pharmacies, and healthcare providers primarily in Japan, with additional operations in Asia through subsidiaries. Founded in 1932 and headquartered in Nagoya, Japan, Suzuken maintains a dominant position in the domestic pharmaceutical wholesale market, handling approximately 20% of Japan's pharmaceutical distribution volume. Its business segments include pharmaceutical wholesaling, manufacturing, retail pharmacy operations, and healthcare IT solutions targeting institutional and retail customers across urban and rural regions. In recent developments, Suzuken has expanded its generic drug portfolio through strategic investments in manufacturing facilities and partnerships with international generic producers; completed the acquisition of a regional wholesaler in 2024 to strengthen its supply network in western Japan; and launched new digital platforms for inventory management and e-procurement services aimed at improving efficiency for healthcare providers. The company also formed alliances with technology firms for AI-driven drug traceability systems and announced a capital investment in sustainable logistics infrastructure in response to regulatory changes in pharmaceutical distribution as of late 2025.